On April 1, Lotte Biologics announced that it has signed a Contract Development and Manufacturing Organization (CDMO) agreement with a US-based biotechnology company specializing in oncology for the production and process development of antibody drug substances.


Lotte Biologics Signs Antibody CDMO Agreement with US Oncology Biotech Company View original image

Under this agreement, Lotte Biologics will be responsible for producing antibody samples required for global late-phase clinical trials and optimizing large-scale processes. The company will support these efforts through its Syracuse Bio Campus in New York, USA.


The company explained that this agreement is significant as it is a project that considers not only clinical sample production but also subsequent clinical and commercialization stages. For antibody therapeutics, establishing the initial process is regarded as a key factor for successful commercialization. Lotte Biologics plans to reliably support clinical and commercialization preparation for the candidate material through its proven manufacturing capabilities and large-scale production facilities.


Lotte Biologics is utilizing the Syracuse Bio Campus as a hub for expanding collaborations with client companies. The company plans to further strengthen its customer-tailored integrated CDMO services and supply chain management (SCM) capabilities based on integrated quality operations across both campuses, by linking them with the Songdo Bio Campus, which is scheduled for completion this year.



A representative from Lotte Biologics stated, "This order serves as a stepping stone toward securing large-scale contracts with biotechnology companies specializing in oncology," and added, "We will make every effort to ensure that this leads not only to commercialization but also to additional contract wins."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing